Building the Blueprint: What Psychedelic Trials Need Now

Psychedelic research has arrived at a pivotal turning point. As clinical programs advance and real-world data emerges, the field is actively learning how to refine its methodologies and elevate standard practices. Still, many core components ranging from protocol design and therapeutic delivery models to transparent stakeholder communication are rapidly evolving. Navigating this shift requires a clear look at recent regulatory feedback.

In this "Bold Conversations" session, a panel of psychedelic science experts breaks down key takeaways from recent regulatory reviews and translates those insights into actionable strategies.